Vosoritide Side Effects: What the Studies Report
Explore vosoritide side effects based on clinical studies and understand the potential risks and benefits of this peptide therapy.
By PeptidesDB EditorialPublished Nov 8, 2026Updated Nov 10, 20269 min read
Vosoritide side effects are a critical consideration for those exploring this peptide therapy, particularly in the context of treating growth disorders. Vosoritide, an FDA-approved peptide, is designed to stimulate growth plate chondrocytes, potentially increasing growth velocity in children with conditions like hypochondroplasia. While clinical studies have demonstrated its efficacy in enhancing growth, the evidence on side effects remains sparse. Some reports suggest variability in response, with potential risks such as slipped capital femoral epiphysis in certain cases. As with any therapeutic intervention, understanding these risks is essential for informed decision-making.
The short answer
Vosoritide side effects remain largely underexplored in the available scientific literature. While vosoritide is an FDA-approved peptide used primarily to treat growth disorders such as hypochondroplasia, the detailed side effect profile is not well-documented in the studies reviewed. The evidence pack does not provide comprehensive data on adverse effects, leaving a gap in understanding the full range of potential side effects associated with this therapy.
The studies that do exist primarily focus on the efficacy of vosoritide in increasing growth velocity. For instance, a Phase 3 trial involving 81 children with hypochondroplasia demonstrated a significant increase in growth velocity compared to placebo, but did not extensively report on side effects A Phase 3 Trial of Vosoritide in Children with Hypochondroplasia. Similarly, another study noted that vosoritide did not alter the bone phenotype in children with achondroplasia, yet provided no detailed side effect data Vosoritide Treatment Does Not Change the Robust Bone Phenotype of Children with Achondroplasia.
The limited available data on side effects includes a case report of an inadvertent overdose in an infant, which resulted in no adverse reactions A Case of Inadvertent Overdose of Vosoritide Injection in a Three-Month-Old Infant With Achondroplasia. Additionally, there is a case series suggesting a potential link between vosoritide therapy and slipped capital femoral epiphysis in some children, particularly those with certain genetic mutations Slipped Capital Femoral Epiphysis during Vosoritide Therapy for Short Stature: A Case Series.
For those interested in a deeper understanding of vosoritide, including its mechanism and broader research context, the article What Is Vosoritide? What the Research Actually Shows offers further insights. However, until more comprehensive studies are conducted, the side effect profile of vosoritide will remain incomplete, underscoring the need for cautious consideration when evaluating its use.
What the term actually covers
When discussing "vosoritide side effects," it is crucial to understand the scope of this term, which ideally encompasses any adverse reactions or unintended consequences associated with vosoritide therapy. However, the evidence pack provided lacks specific data on side effects, limiting our ability to comprehensively define this term based on empirical research.
Vosoritide is a peptide therapy primarily used to treat growth disorders such as hypochondroplasia and achondroplasia. While it has been approved by the FDA, the detailed side effect profile remains underexplored in the available scientific literature. The absence of specific side effect data in the studies provided makes it challenging to pinpoint the exact nature and prevalence of any adverse effects.
In the studies included in the evidence pack, there are some indications of potential risks. For instance, a case report involving an inadvertent overdose of vosoritide in a three-month-old infant with achondroplasia reported no adverse reactions, suggesting variability in response among individuals (source). Another observational study noted an association between vosoritide therapy and an increased risk of slipped capital femoral epiphysis in children with certain genetic short stature conditions (source).
Despite these isolated reports, the overall lack of comprehensive data on side effects underscores the need for further research. Future studies should aim to systematically document and analyze side effects in larger, more diverse populations to provide a clearer picture of the safety profile of vosoritide. In the meantime, those considering vosoritide therapy should consult healthcare professionals and consider using tools like the Peptide reconstitution calculator for accurate dosing and administration.
What the evidence shows
The evidence on vosoritide, particularly concerning its side effects, is limited but provides some insights into its efficacy and safety profile. A Phase 3 trial involving 81 children with hypochondroplasia demonstrated that vosoritide significantly increased growth velocity compared to placebo, with a least squares mean difference of 2.33 cm/year (95% CI, 1.85-2.82 cm/year; P<0.0001) over one year 4191. However, while the trial highlights efficacy, detailed side effect data is not extensively reported, leaving a gap in understanding the full safety profile.
A case report of an inadvertent overdose in a three-month-old infant with achondroplasia, who received a double dose of vosoritide, revealed no adverse reactions, suggesting variability in response among infants 4621. This case underscores the need for further investigation into the safety margins and potential variability in side effects across different age groups and dosages.
Another observational study raised concerns about the risk of slipped capital femoral epiphysis (SCFE) during vosoritide therapy. In a case series involving five children with genetic short stature, two out of twelve participants with Aggrecan mutations developed SCFE, indicating a possible association between vosoritide therapy and this condition 3658.
These studies suggest that while vosoritide shows promise in increasing growth velocity, the side effect profile remains underexplored. The variability in response and potential risks, such as SCFE, highlight the importance of further research to establish a comprehensive understanding of vosoritide's safety. For those considering peptide therapies, consulting resources like Are peptides safe? can provide additional context on the broader safety considerations.
How to think about risk
When considering the risks associated with vosoritide, it is crucial to understand the variability in response and the specific risks identified in existing case reports. Vosoritide is primarily used to treat growth disorders, but the side effect profile is not fully elucidated, which necessitates a cautious approach.
One notable risk involves the potential for slipped capital femoral epiphysis (SCFE). A case series involving five children with genetic short stature, including those with Turner syndrome and Aggrecan mutations, highlighted this concern. The study reported that 2 out of 12 participants with ACAN mutations developed SCFE during vosoritide therapy, indicating a possible link between the treatment and this condition source. This finding underscores the importance of monitoring bone health in patients receiving vosoritide.
Furthermore, a case report described an inadvertent overdose of vosoritide in a three-month-old infant with achondroplasia. Despite receiving a double dose, the infant exhibited no adverse reactions, suggesting variability in how individuals might respond to the peptide source. This variability complicates risk assessment and highlights the need for personalized medical supervision.
Given these findings, it is essential for patients and healthcare providers to engage in thorough discussions about the potential risks and benefits of vosoritide therapy. For more detailed information on the compound, the vosoritide profile offers insights into its pharmacology and approved uses. Additionally, consulting resources like the Are peptides safe? guide can provide broader context on peptide therapy safety.
Vosoritide side effects: What this site does and does not claim
This site aims to provide a comprehensive overview of vosoritide, but it is important to recognize the limitations in the available evidence regarding its side effects. The research library includes studies focusing on the efficacy of vosoritide, such as its ability to increase growth velocity in children with hypochondroplasia, as demonstrated in a Phase 3 trial involving 81 participants A Phase 3 Trial of Vosoritide in Children with Hypochondroplasia. However, detailed data on side effects are notably sparse.
The existing studies primarily address efficacy and some safety concerns, but they do not offer an exhaustive profile of potential adverse effects. For instance, a case report involving a three-month-old infant who received an inadvertent overdose of vosoritide showed no adverse reactions, highlighting variability in response A Case of Inadvertent Overdose of Vosoritide Injection in a Three-Month-Old Infant With Achondroplasia. Additionally, an observational study suggested a possible link between vosoritide therapy and an increased risk of slipped capital femoral epiphysis in certain children Slipped Capital Femoral Epiphysis during Vosoritide Therapy for Short Stature: A Case Series.
While these findings provide some insights, they do not constitute a comprehensive safety profile. The absence of detailed side effect data means that any claims about vosoritide's safety are limited to what is currently documented. Future research, especially large-scale, long-term studies, is necessary to better understand the full range of vosoritide side effects. Until such data are available, it is crucial for users to consult healthcare providers and consider the broader context of peptide therapy safety, as discussed in our Are peptides safe? guide.
Common questions
One common question about vosoritide concerns its side effects, given the limited data available. While vosoritide is FDA-approved for treating growth disorders like hypochondroplasia, the detailed side effect profile is not well-documented. This lack of comprehensive data leaves potential users and healthcare providers with questions about its safety and long-term effects.
What are the known side effects?
The evidence pack does not provide a detailed list of side effects. However, some studies highlight specific concerns. A case report involving a three-month-old infant who received an accidental overdose of vosoritide showed no adverse reactions, suggesting variability in response (source). Another observational study noted that vosoritide therapy might be linked to an increased risk of slipped capital femoral epiphysis (SCFE) in children with genetic short stature, particularly those with Turner syndrome and Aggrecan mutations (source).
How does vosoritide affect bone growth?
Vosoritide is designed to stimulate growth plate chondrocytes, potentially increasing growth velocity. A Phase 3 trial demonstrated significant growth velocity increases in children with hypochondroplasia (source). However, another observational study found that vosoritide did not alter the robust bone phenotype in children with achondroplasia over five years (source).
Are there long-term safety data?
Currently, long-term safety data are sparse. The existing studies focus primarily on short-term outcomes and efficacy. More extensive, long-term studies are necessary to fully understand the safety profile of vosoritide. For those considering vosoritide, consulting with healthcare providers and reviewing available resources, such as the vosoritide profile and Are peptides safe?, can provide additional guidance.
Where to go from here
For those considering vosoritide therapy, the next steps should involve a thorough consultation with healthcare professionals who can provide personalized advice based on the most current research and individual health needs. Given the limited data on vosoritide side effects, it is crucial to weigh the potential benefits against the risks, especially in the context of growth disorders like hypochondroplasia and achondroplasia.
Vosoritide has demonstrated efficacy in increasing growth velocity in children with hypochondroplasia, as evidenced by a Phase 3 trial involving 81 participants 4191. However, the side effect profile remains underexplored, with some case reports indicating potential risks such as slipped capital femoral epiphysis 3658. These findings underscore the importance of individualized risk assessment and monitoring during treatment.
For those new to peptide therapies, understanding the broader context of peptide safety is essential. Our Are peptides safe? guide provides insights into the general safety considerations for peptide use. Additionally, the vosoritide profile page offers a detailed overview of this specific peptide, including its mechanism of action and current research status.
Finally, for practical considerations such as dosing, our Peptide reconstitution calculator can assist in ensuring accurate preparation, though it should never replace professional medical advice. As research continues to evolve, staying informed through reliable sources and ongoing discussions with healthcare providers will be key to making informed decisions about vosoritide therapy.
Compounds covered